Document is current
Any future updates will be listed below
-
Authors
de Andrade, Joao A. https://orcid.org/0000-0002-3743-4561
Kulkarni, Tejaswini
Neely, Megan L.
Hellkamp, Anne S.
Case, Amy Hajari
Culver, Daniel A.
Guntupalli, Kalpalatha
Bender, Shaun
Conoscenti, Craig S.
Snyder, Laurie D.
,
Baker, Albert
Beegle, Scott
Belperio, John A.
Condos, Rany
Cordova, Francis
Culver, Daniel A.
Dilling, Daniel
Fitzgerald, John
Silhan, Leann
Flaherty, Kevin R.
Gibson, Kevin
Gulati, Mridu
Guntupalli, Kalpalatha
Gupta, Nishant
Case, Amy Hajari
Hotchkin, David
Huie, Tristan J.
Kaner, Robert J.
Kim, Hyun J.
Lancaster, Lisa H.
Steele, Mark
Lasky, Joseph A.
Lee, Doug
Liesching, Timothy
Lipchik, Randolph
Lobo, Jason
Luckhardt, Tracy R.
de Andrade, Joao A. https://orcid.org/0000-0002-3743-4561
Mageto, Yolanda
Huang, Howard
Menon, Prema
Mageto, Yolanda
Namen, Andrew
Oldham, Justin M.
Paul, Tessy
Zhang, David
Podolanczuk, Anna
Lederer, David
Patel, Nina M.
Porteous, Mary
Kreider, Maryl
Raj, Rishi
Mohabir, Paul
Ramaswamy, Murali
Russell, Tonya
Sachs, Paul
Safdar, Zeenat
Shafazand, Shirin
Glassberg, Marilyn
Siddiqi, Ather
Asi, Wael
Sigal, Barry
Strek, Mary E.
Suliman, Sally
Roman, Jesse
Tabak, Jeremy
Walia, Rajat
Whelan, Timothy P. M.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01915511 at ClinicalTrials.govDocuments that mention this clinical trial
Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
https://doi.org/10.1136/bmjresp-2015-000108
Hospitalizations in patients with idiopathic pulmonary fibrosis
https://doi.org/10.1186/s12931-021-01851-4
Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
https://doi.org/10.1007/s00408-021-00506-x
Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
https://doi.org/10.1186/s12931-021-01921-7
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
https://doi.org/10.1136/bmjresp-2020-000567
-
Funding
Funding for this research was provided by:
The IPF-PRO/ILD-PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and co-ordinated by the Duke Clinical Research Institute (DCRI).
- License Information
-
More Information
Article History
Received: 6 May 2021
Accepted: 28 December 2021
First Online: 7 January 2022
Declarations
:
: The study was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was also approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrollment at each site listed in the “Acknowledgments”. All patients provided informed consent.
: Not applicable.
: JAdA reports personal fees from BI. TK reports speaker fees from BI. MLN, ASH and LDS are faculty members at DCRI, which receives funding from BIPI to coordinate the IPF-PRO/ILD-PRO Registry. AHC reports personal fees and non-financial support from BI, personal fees from Genentech, and non-financial support from DCRI. DAC reports personal fees from BI and Genentech. KG has nothing to disclose. SB and CSC are employees of BIPI.
